EFTA00586852Set 9
90p36,976w
this taxonomy will
allow for highly accurate and differentiated diagnostics. The sequencing-based molecular
diagnostics market is expected to grow at a CAGR of 72% from 5511m ... Anacor. At BMGF, Boris also led discovery program of novel
diagnostics platform technologies, molecular diagnostics point-of-care applications, novel
STRICTLY CONFIDENTIAL 16
EFTA00586872
immunological detection systems, vaccination and surveillance ... Artis Ventures and Laboratory Corporation of America.
Invitae
Inviate is a molecular diagnostic company started by Randy Scott in 2012. Specializing in genetic
diagnostics for hereditary disorders, Invitae is making
https://www.justice.gov/epstein/files/DataSet%209/EFTA00586852.pdf
EFTA00906003Set 9
2011-03-162p578w
Intelligent Medical Devices, Inc. (IMDx) Finalize cGMP Oligo Supply and Licensing
Agreements for Molecular Diagnostic Testing (IVD) Products.
NOVATO, CA and CAMBRIDGE, MA (Monday, March 14, 2011) — Biosearch Technologies ... Biosearch), a leading
supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, and IMDx
(privately held), a developer and manufacturer of innovative, clinically impactful molecular test solutions ... expertise in fully assembled RUO kits and
the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is
registered with the FDA (registration number 3003009025), and as such
https://www.justice.gov/epstein/files/DataSet%209/EFTA00906003.pdf
EFTA01196229Set 9
13p4,675w
science VCs. At BMGF, he also led a discovery program of novel
diagnostics platforms, molecular diagnostics point-of-care applications, immunological detection
systems, vaccinations and surveillance technologies.
Prior to joining
https://www.justice.gov/epstein/files/DataSet%209/EFTA01196229.pdf
EFTA00930939Set 9
2012-03-133p654w
women."
Under the leadership of Dr. Jacobs, IMDx designs, develops, and manufactures clinically relevant molecular
diagnostics for rapid and accurate detection of diseases. In 2011, IMDx released two CE-marked ... IMDx grows and expands its menu offerings, becoming a larger player in the molecular
diagnostics industry.
EFTA00930939
About IMDx
Based in Cambridge, MA, IMDx ( ) is an innovative company that designs ... develops
and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically
impactful and competitively differentiated for a range of disease areas for current and next generation systems
https://www.justice.gov/epstein/files/DataSet%209/EFTA00930939.pdf
EFTA00718974Set 9
2012-03-132p705w
women."
Under the leadership of Dr. Jacobs, IMDx designs, develops, and manufactures clinically relevant molecular
diagnostics for rapid and accurate detection of diseases. In 2011, IMDx released two CE-marked ... IMDx grows and expands its menu offerings, becoming a larger player in the molecular
diagnostics industry.
EFTA00718974
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that ... designs, develops
and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically
impactful and competitively differentiated for a range of disease areas for current and next generation
https://www.justice.gov/epstein/files/DataSet%209/EFTA00718974.pdf
EFTA00648481Set 9
2011-01-212p669w
single
automated instrument system," says Stafford O'Kelly, head of Abbott's molecular diagnostics business.
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops ... manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and
competitively differentiated for a range of disease areas for current and next generation systems, including targets
https://www.justice.gov/epstein/files/DataSet%209/EFTA00648481.pdf
EFTA00614609Set 9
2011-01-201p379w
single automated instrument system," says Stafford
O'Kelly, head of Abbott's molecular diagnostics business.
About IMDx
Based in Cambridge, MA. IMDx (ww.v.IntelligentMDx.com) is an innovative company that
designs, develops ... manufactures molecular diagnostic products. IMDx has developed
molecular solutions that are clinically impactful and competitively differentiated for a range of
disease areas for current and next generation systems, including targets
https://www.justice.gov/epstein/files/DataSet%209/EFTA00614609.pdf
EFTA00902109Set 9
2011-01-213p622w
single automated instrument system," says Stafford O'Kelly, head of Abbott's molecular diagnostics business.
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops ... manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and
competitively differentiated for a range of disease areas for current and next generation systems, including targets
https://www.justice.gov/epstein/files/DataSet%209/EFTA00902109.pdf
EFTA00640072Set 9
2011-01-202p505w
single
automated instrument system," says Stafford O'Kelly, head of Abbott's molecular diagnostics business.
About IMDx
Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops ... manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and
competitively differentiated for a range of disease areas for current and next generation systems, including targets
https://www.justice.gov/epstein/files/DataSet%209/EFTA00640072.pdf
EFTA00593752Set 9
19p3,543w
development of diagnostics models that are transforming the delivery
and therapeutics of healthcare:
• Molecular diagnostics allowing for highly precise • Accountable care organizations and other
and accurate diagnosis and prevention outcome ... agriculture and substance production)
$20B in Sequencing Technology and Apps CLEAR VALUE
$8B in Molecular Diagnostics PROPOSITION
and use case for
payors
Sources: Mckinsey, IIlumina, BCC Research, Research and Markets
https://www.justice.gov/epstein/files/DataSet%209/EFTA00593752.pdf
EFTA00317063Set 9
18p1,115w
Individualized cancer care
through
molecular diagnostics
Dr. Francis Barany
Weill Cornell Medical College
Confidential, October 2011
EFTA00317063
Our technology will guide physician decision
in cancer prevention, early detection, and
therapy ... Award, Cornell University in 2011.
Confidential, October 2011 16
EFTA00317078
Individualized cancer care through molecular
diagnostics.
Contact Information:
Dr. Francis Barany
Director
Hidden Cancer Project
Department of Microbiology
& Immunology
Weill
https://www.justice.gov/epstein/files/DataSet%209/EFTA00317063.pdf
EFTA00614047Set 9
18p1,115w
Individualized cancer care
through
molecular diagnostics
Dr. Francis Barany
Weill Cornell Medical College
Confidential, October 2011
EFTA00614047
Our technology will guide physician decision
in cancer prevention, early detection, and
therapy ... Award, Cornell University in 2011.
Confidential, October 2011 16
EFTA00614062
Individualized cancer care through molecular
diagnostics.
Contact Information:
Dr. Francis Barany
Director
Hidden Cancer Project
Department of Microbiology
& Immunology
Weill
https://www.justice.gov/epstein/files/DataSet%209/EFTA00614047.pdf
EFTA00747252Set 9
2010-03-242p742w
rapid assay solution that is flexible and adaptable to the wider
needs of molecular diagnostics laboratory customers," said Alice Jacobs, M.D., IMDx, Chairman & CEO.
About the FDA's Emergency ... sooner or renewed.
kbout IntelligentMDx (IMDx)
IMDx utilizes a proprietary bioinformatics process to design molecular diagnostic assays. This process affords
shorter design times, and results in more robust assays. IMDx
https://www.justice.gov/epstein/files/DataSet%209/EFTA00747252.pdf
EFTA00747269Set 9
2010-03-242p679w
rapid assay solution that is flexible and adaptable to the wider
needs of molecular diagnostics laboratory customers," said Alice Jacobs, M.D., IMDx, Chairman & CEO.
About the FDA's Emergency ... sooner or renewed.
About IntelligentMDx (IMDx)
IMDx utilizes a proprietary bioinformatics process to design molecular diagnostic assays. This process affords
shorter design times, and results in more robust assays. IMDx
https://www.justice.gov/epstein/files/DataSet%209/EFTA00747269.pdf
EFTA00761710Set 9
2010-03-242p563w
rapid assay solution that is flexible and adaptable to the wider needs of
molecular diagnostics laboratory customers," said Alice Jacobs, M.D., IMDx, Chairman & CEO.
About the FDA's Emergency ... sooner or renewed.
About IntelligentMDx (IMDx)
IMDx utilizes a proprietary bioinformatics process to design molecular diagnostic assays. This process affords
shorter design times, and results in more robust assays. IMDx
https://www.justice.gov/epstein/files/DataSet%209/EFTA00761710.pdf
EFTA00761695Set 9
2010-03-242p631w
rapid assay solution that is flexible and adaptable to the wider needs of
molecular diagnostics laboratory customers," said Alice Jacobs, M.D., IMDx, Chairman & CEO.
About the FDA's Emergency ... sooner or renewed.
About IntelligentMDx (IMDx)
IMDx utilizes a proprietary bioinformatics process to design molecular diagnostic assays. This process affords
shorter design times, and results in more robust assays. IMDx
https://www.justice.gov/epstein/files/DataSet%209/EFTA00761695.pdf